Evolus (EOLS) Rating Lowered to Sell at Zacks Investment Research
Evolus (NASDAQ:EOLS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “
EOLS has been the topic of several other research reports. Cantor Fitzgerald set a $35.00 target price on Evolus and gave the stock a “buy” rating in a research report on Friday, August 17th. SunTrust Banks reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Monday, August 6th. JMP Securities reissued an “outperform” rating and set a $35.00 target price on shares of Evolus in a research report on Thursday, August 2nd. Mizuho raised their target price on Evolus from $16.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, June 11th. Finally, ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Evolus presently has a consensus rating of “Buy” and an average target price of $30.40.
Evolus (NASDAQ:EOLS) last issued its earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.05). research analysts forecast that Evolus will post -1.76 earnings per share for the current fiscal year.
In other Evolus news, major shareholder Corp Alphaeon sold 1,000,000 shares of Evolus stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $18.80, for a total transaction of $18,800,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kristine Romine purchased 10,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The shares were purchased at an average cost of $19.83 per share, for a total transaction of $198,300.00. The disclosure for this purchase can be found here.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Evolus during the second quarter worth approximately $108,000. Tower Research Capital LLC TRC increased its position in Evolus by 761.4% during the second quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after buying an additional 5,794 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Evolus during the second quarter worth approximately $258,000. Alpine Woods Capital Investors LLC acquired a new position in Evolus during the second quarter worth approximately $280,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in Evolus during the second quarter worth approximately $303,000. 13.20% of the stock is currently owned by institutional investors.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
See Also: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.